13F-HR filed by Patient Square Capital LP
Patient Square Capital LP filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-14, with 19 holding rows worth $241,723,318.
- Accession
- 0000950123-25-005195
- Filer
- CIK 1819257
- Filed
- 2025-05-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2025
A holdings report, 19 entries on the cover page, a total value of $241,723,318 stated on the cover page (in dollars after the unit check, H1), rows summing to $241,723,318 with VALUE read as dollars as filed, 13F file number 028-22927. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ROIVANT SCIENCES LTD | G76279101 | SHS | 12,480,000 | $125,923,200 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 330,250 | $25,194,773 | dollars as filed | |
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 1,522,452 | $22,456,167 | dollars as filed | |
| EYEPOINT INC COM NEW | 30233G209 | Stock | 1,481,977 | $8,032,315 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 920,199 | $6,745,059 | dollars as filed | |
| CULLINAN THERAPEUTICS INC | 230031106 | COM | 878,897 | $6,653,250 | dollars as filed | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 447,296 | $5,313,876 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 116,362 | $5,242,108 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 253,838 | $4,995,532 | dollars as filed | |
| SCHOLAR ROCK HLDG CORP | 80706P103 | COM | 154,000 | $4,951,100 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 83,000 | $4,120,120 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 139,732 | $4,094,148 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 142,201 | $3,892,041 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 245,496 | $3,854,287 | dollars as filed | |
| ALLOGENE THERAPEUTICS INC | 019770106 | COM | 2,368,186 | $3,457,552 | dollars as filed | |
| BLUEPRINT MEDICINES CORP | 09627Y109 | COM | 38,500 | $3,407,635 | dollars as filed | |
| INTELLIA THERAPEUTICS INC | 45826J105 | COM | 232,781 | $1,655,073 | dollars as filed | |
| SOLENO THERAPEUTICS INC | 834203309 | COM | 18,600 | $1,328,970 | dollars as filed | |
| VYNE THERAPEUTICS INC | 92941V308 | COM | 257,033 | $406,112 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-25-005195 | this filing | 2025-05-14 | acceptance time not in the bulk data set |